Beta-blockers are under-prescribed in patients with chronic obstructive pulmonary disease and co-morbid cardiac disease

Internal Medicine Journal

Volumn 46, Issue 11, 2016, Pages 1336-1340

  Neef, P A ^a   McDonald, C F ^b,c   Burrell, L M ^c   Irving, L B ^c,d   Johnson, D F ^a,c   Steinfort, D P ^c,d  

^a General Medicine   (Australia)

^b AUSTIN HEALTH   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MELBOURNE HEALTH   (Australia)

Author keywords

beta blocker; cardiovascular disease; chronic obstructive pulmonary disease; COPD; prescription

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BRONCHODILATING AGENT; CARVEDILOL; METOPROLOL; NEBIVOLOL;

AGED; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ASSESSMENT; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; DRUG INDICATION; FEMALE; HEART DISEASE; HOSPITAL ADMISSION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MANAGED CARE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TERTIARY CARE CENTER; TREATMENT INDICATION; AUSTRALIA; HEART FAILURE; HOSPITALIZATION; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICS AND NUMERICAL DATA;

ADRENERGIC BETA-ANTAGONISTS; AGED; AUSTRALIA; COMORBIDITY; DRUG PRESCRIPTIONS; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES;

EID: 84994162809     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.13240     Document Type: Article

References (33)

1. Steg G, James S, Atar D, Badano L, Blomstrom-Lundqvist C, Borger M et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012; 33: 2569–619.
2. McMurray J, Adamopoulous S, Anker S, Auricchio A, Bohm M, Dickstein K et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012. Eur Heart J Heart Fail 2012; 14: 803–69.
3. Chew D, Aroney C, Aylward P, Kelly A, White H, Tideman P et al. 2011 Addendum to the National Heart Foundation of Australia/Cardiac Society of Australia and New Zealand Guidelines for the management of acute coronary syndromes (ACS) 2006. Heart Lung Circ 2011; 20: 487–502.
4. National Heart Foundation of Australia and the Cardiac Society of Australia and New Zealand (Chronic Heart Failure Guidelines Expert Writing Panel). Guidelines for the prevention, detection and management of chronic heart failure in Australia. 2011.
5. Yancy C, Jessup M, Bozkurt B, Butler J, Casey D, Drazner M et al. ACCF/AHA guideline for the management of heart failure. J Am Coll Cardiol 2013; 16: e147–239.
6. Fihn S, Gardin J, Abrams J, Berra K, Blankenship J, Dallas A et al. ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease. J Am Coll Cardiol 2012; 60: e44–164.
7. Salpeter S, Ormiston T, Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005; CD003566.
8. Hunt S, Abraham W, Chin M, Feldman A, Francis G, Ganiats T et al. Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults. J Am Coll Cardiol 2009; 53: e1–90.
9. Quint J, Herrett E, Bhaskaran K, Timmis A, Hemingway H, Wedzicha J et al. Effect of β blockers on mortality after myocardial infarction in adults with COPD: population based cohort study of UK electronic healthcare records. BMJ 2013; 347: f6650.
10. Angeloni E, Melina G, Roscitano A, Refice S, Capuano F, Lechiancole A et al. β-Blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg 2013; 95: 525–32.
11. Van Gestel Y, Hoeks S, Stam H, Mertens F, BAx J, Van Domburg R et al. Beta-blockers and health-related quality of life in patients with peripheral artery disease and COPD. Int J Chron Obstruct Pulmon Dis 2009; 4: 177–83.
12. Mentz R, Wojdyla D, Fiuzat M, Chiswell K, Fonarow G, O'Connor C. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol 2013; 111: 582–7.
13. Anthonisen N, Connett J, Enright P, Manfreda J, Lung Health Study Research Group. Hospitalisations and mortality in the Lung Health Study. Am J Respir Crit Care Med 2002; 166: 333–9.
14. Wise R, Mcgarvey L, John M, Anderson J, Zvarich M. Reliability of cause-specific mortality adjudication in a COPD clinical trial. In: Program and Abstracts of the American Thoracic Society 2006 International Conference, San Diego, CA; 2006.
15. Stefan M, Bannuru R, Lessard D, Gore J, Lindenauer P, Goldberg R. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction. Chest 2012; 141: 1441–8.
16. Swennen M, Rutten F, Kalkman C, Van der Graaf Y, Sachs A, Van der Heijden G. Do general practitioners follow treatment recommendations from guidelines in their decisions on heart failure management? A cross-sectional study. BMJ Open 2013; 3: e002982.
17. Peters J, Gomez-Dinger P, Freeman G, Smith PB. Use of beta-blockers in congestive heart failure (CHF) patients with COPD and/or asthma. Chest 2004; 126: 921S.
18. Jones T, Ruffin R, Arstall M. Cardiologists are more willing to prescribe β-blockers than respiratory physicians: an Australasian clinical scenario study. Intern Med J 2013; 43: 507–12.
19. Albouaini K, Andron M, Alahmar A, Egred M. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int J Chron Obstruct Pulmon Dis 2007; 2: 535–40.
20. Suissa SDAS, Ernst P. Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax 2012; 67: 957–63.
21. Mannino D, Doherty D, Sonia BA. Global Initiative on Obstructive Lung Disease (GOLD) classification of lung disease and mortality: findings from the Atherosclerosis Risk in Communities (ARIC) study. Respir Med 2006; 100: 115–22.
22. Cochrane B, Quinn S, Walters H, Young I. Investigating the adverse respiratory effects of beta-blocker treatment: six years of prospective longitudinal data in a cohort with cardiac disease. Intern Med J 2012; 42: 786–93.
23. Chen J, Radford M, Wang Y, Marciniak T, Krumholz H. Effectiveness of beta-blocker therapy after acute myocardial infarction in elderly patients with chronic obstructive pulmonary disease or asthma. J Am Coll Cardiol 2001; 37: 1950–6.
24. Etminan M, Jafari S, Carleton B, Fitzgerald J. Beta-blocker use and COPD mortality: a systematic review and meta-analysis. BMC Pulm Med 2012; 12: 48.
25. Dransfield M, Rowe S, Johnson J, Bailey W, Gerald L. Use of β-blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301–5.
26. Short P, Lipworth S, Elder D, Schembri S, Lipworth B. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ 2011; 342: d2549.
27. Olenchock B, Fonarow G, Pan W, Hernandez A, Cannon C. Current use of beta-blockers in reactive airways disease who are hospitalised with acute coronary syndrome. Am J Cardiol 2009; 103: 295–300.
28. Rutten F, Zuithoff N, Hak E, Grobbee D, Hoes A. β-Blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010; 170: 880–7.
29. Bhatt S, Wells J, Kinney G, Washko G Jr, Budoff M, Kim Y et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax 2016; 71: 8–14.
30. Farland M, Peters C, Williams J, Bielak K, Heidel R, Ray S. β-Blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother 2013; 47: 651–656.
31. Gottleib S, McCarter R, Vogel R. Effect of beta-blockade on mortality among high-risk and low-risk patients after myocardial infarction. N Engl J Med 1998; 339: 489–97.
32. Postma D, Boezen H. Rationale for the Dutch hypothesis: allergy and airway hyperresponsiveness as genetic factors and their interaction with the environment in the development of asthma and COPD. Chest 2004; 126: 96–104.
33. Postma D, Reddel H, ten Hacken N, van den Berge M. Asthma and chronic obstructive pulmonary disease: similarities and differences. Clin Chest Med 2014; 35: 143–56.